NCT02812251View on ClinicalTrials.gov

Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 7, 2016

Primary Completion Date

November 17, 2016

Study Completion Date

November 17, 2016

Conditions
Healthy
Interventions
DRUG

JNJ-61393215

JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.

DRUG

Placebo

Matching placebo will be administered.

Trial Locations (1)

Unknown

Leiden

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY